logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2020
Therapix Biosciences Ltd.
Top line results from phase IIb, placebo-controlled 12-week clinical trial of THX-110
Tourette Syndrome TS
Q3 2020
Otonomy Inc.
Top-line results from phase III trial of OTIVIDEX
Ménière's disease
2H 2020
Aridis Pharmaceuticals Inc
Interim data from phase III pivotal trial of AR-301
Acute pneumonia caused by S. aureus infection
2H 2020
CHIASMA, INC
Top-line data from phase III clinical trial of octreotide capsules (MPOWERED)
Adult patients with acromegaly
2H 2020
MyoKardia Inc
Topline results from phase III study of Mavacamten (EXPLORER-HCM trial)
Hypertrophic Cardiomyopathy
2H 2020
Iovance Biotherapeutics, Inc.
Submission of BLA for LN-144
Metastatic melanoma
Q3 2020
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III MuSK-MG trial of Firdapse
Myasthenia gravis patients with autoantibodies to muscle-specific tyrosine kinase (MuSK)
2H 2020
Onconova Therapeutics, Inc
Top-line data from phase III pivotal trial of intravenous Rigosertib (INSPIRE)
Myelodysplastic Syndromes
2H 2020
SCYNEXIS, Inc.
Filing of initial NDA for oral Ibrexafungerp
Vulvovaginal candidiasis
2H 2020
Vaccinex, Inc.
Data from phase II study of VX15/2503 ( SIGNAL)
Early manifest and late prodromal Huntington's disease
2H 2020
Neon Therapeutics, Inc.
Immune monitoring data from phase Ib trial of NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab
Advanced or metastatic melanoma
2H 2020
ChemoCentryx Inc.
Top-line data from phase II trial of Avacopan
kidney disease C3 Glomerulopathy (C3G)
2H 2020
Syndax Pharma
Initial results from phase I dose escalation trial of SNDX-6352
Chronic graft versus host disease (cGVHD)
2H 2020
Wave Life Sciences Ltd.
Topline data readout from Phase 1b/2a clinical trial of WVE-120101 (PRECISION-HD)
Huntington's disease
Q3 2020
Immunic, Inc
Topline Data from phase II study of IMU-838 (EMPhASIS)
Relapsing-remitting multiple sclerosis
2H 2020
Equillium Inc.
Data from phase Ib/II clinical trial of EQ001 (EQUATE)
Patients with aGVHD
Q3 2020
Neon Therapeutics, Inc.
Data from phase Ib trial of NEO-PV-01 and Keytruda
Advanced or metastatic nonsquamous non-small cell lung carcinoma
2H 2020
Hookipa Pharma Inc.
Preliminary efficacy data from phase II clinical trial of HB-101
Prophylactic vaccine for Cytomegalovirus
Q3 2020
Acasti Pharma, Inc.
Top line results from phase III trial to evaluate safety and efficacy of CaPre (TRILOGY 2)
Severe hypertriglyceridemia
2H 2020
Equillium Inc.
Topline data from phase Ib proof-of-concept trials of EQ001 (EQUIP)
Uncontrolled asthma
2H 2020
Autolus Therapeutics plc
Initial data from phase I study of AUTO4
T-cell lymphoma
2H 2020
Harpoon Therapeutics Inc.
Interim results from phase I clinical trial of HPN424
Metastatic castration-resistant prostate cancer
2H 2020
Harpoon Therapeutics Inc.
Proof of concept data from phase I/IIa trial of HPN536
Ovarian and other mesothelin-expressing solid tumors
2H 2020
NovoCure
Data from phase II trial to test efficacy and safety of TTFields (HEPNOVA)
Advanced hepatocellular cancer
2H 2020
NovoCure
Interim analysis from pivotal, phase III trial to test the efficacy and safety of TTFields (LUNAR)
Second-line treatment of patients with non-small cell lung cancer.